Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ANG 3777

Drug Profile

ANG 3777

Alternative Names: ANG-3777; BB 3; Refanalin

Latest Information Update: 09 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Angion Biomedica
  • Class Cardiovascular therapies; Small molecules; Urologics
  • Mechanism of Action Hepatocyte growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal failure
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Delayed graft function
  • Phase II Acute kidney injury; Renal failure
  • No development reported Heart failure
  • Discontinued Hepatic fibrosis; Myocardial infarction; Stroke

Most Recent Events

  • 04 Jan 2019 BB 3 is now called ANG 3777
  • 12 Nov 2018 BB3 licensed to Sinovant Sciences in China, Hong Kong, Macau and Taiwan
  • 12 Nov 2018 Sinovant Sciences announces intention to submit regulatory applications for Delayed graft function and Acute kidney injury in China, Hong Kong, Macau, and Taiwan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top